Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials.

摘要: Background Many patients with borderline personality disorder receive pharmacological treatment, but there is uncertainty about the usefulness of such therapies. Aims To evaluate evidence effectiveness pharmacotherapy in treating different facets psychopathology disorder. Method A Cochrane Collaboration systematic review and meta-analysis randomised comparisons drug v. placebo, drug, or single combined treatment adult was conducted. Primary outcomes were overall severity as well specific core symptoms. Secondary comprised associated psychiatric pathology tolerability. Results Twenty-seven trials included which first- second-generation antipsychotics, mood stabilisers, antidepressants omega-3 fatty acids tested. Most beneficial effects found for stabilisers topiramate, lamotrigine valproate semisodium, antipsychotics aripiprazole olanzapine. However, robustness findings low, since they are based mostly on single, small studies. Selective serotonin reuptake inhibitors so far lack high-level effectiveness. Conclusions The current from controlled suggests that especially may be effective a number symptoms psychopathology, does not currently support Pharmacotherapy should therefore targeted at